Divalproex Sodium Tablet, Delayed Release
Product Images NDC 68084-776

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68084-776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

250 mg Blister

250 mg Blister
FDA Label Image

250 mg Carton

250 mg Carton
This is a medication called Divalproex Sodium, which comes in a delayed-release tablet form. It is prescribed through a medical professional and comes in a bottle containing 100 tablets. The medication guide should be included with each patient's prescription. The tablets contain Divalproex sodium equivalent to valproic acid, with a standard dosage specified in the package insert. It should be stored at a temperature between 20° to 25°C and kept away from children. The package should not be used if the blister is torn or broken. The drug product is manufactured and packaged by American Health Packaging in Columbus, Ohio.*
FDA Label Image

500 mg Blister

500 mg Blister
FDA Label Image

500 mg Carton

500 mg Carton
This is a medication package of Divalproex Sodium Delayed-Release Tablets, USP with Valproic Acid Activity. The tablets come in 500mg strength and there are 90 tablets in total (9 x 10) for prescription use only. Each enteric-coated tablet contains Divalproex sodium USP equivalent to valproic acid. The usual dosage should be seen in the package insert. It is important to keep the tablets out of reach of children and do not use if the blister pack is torn or broken. Store between 20 to 25°C (68 to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be accompanied by a medication guide to be given to each patient. The package was distributed by American Health Packaging based in Columbus, Ohio.*
FDA Label Image

Ahp77601

Ahp77601
FDA Label Image

Ahp78261

Ahp78261
FDA Label Image

Figure 1

Figure 1
FDA Label Image

Figure 2

Figure 2
The text describes a figure, specifically Figure 2, showing the reduction in CPS rate. The figure displays two sets of data: one for Divaproex Sodium DefayedRelease Tablets and the other for Placsbo. The figure also includes a bar graph with levels ranging from 0 to 50 and a section indicating that 9% of patients improved, while some experienced no change, and some worsened.*
FDA Label Image

Figure 3

Figure 3
The text describes a figure or graph named "Reduction In CPS Rate" represented by Figure 3. The graph shows two categories or groups, "High Dose" and "Low Dose" with their respective percentage values. It also includes three sections "Improvement," "No Change," and "Worsening" that depict the percentage of patients who experienced these outcomes.*
FDA Label Image

Figure 4

Figure 4
This is a figure showing the mean 4-week migraine rates for two studies on the effects of placebo and divalproex sodium delayed-release tablets. The mean dose for divalproex sodium delayed-release tablets was 1,087 mg/day in Study 1 and the dose varied between 500 or 1,000 mg/day in Study 2.*
FDA Label Image

Structure

Structure

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.